<DOC>
	<DOCNO>NCT01853787</DOCNO>
	<brief_summary>- Among many cause , Bronchial obstruction Chronic Obstructive Pulmonary Disease ( COPD ) also cause inflammation peripheral airway wall . - Neutrophils inflammatory mediator like Interleukin-6 ( IL6 ) , Interleukin-8 ( IL8 ) , Interleukin-1 alpha ( IL-1 alpha ) , Interleukin-1beta ( IL-1 beta ) , Tumor Necrosis Factor alfa ( TNF-alfa ) , Reactive Oxygen Species ( ROS ) , Leukotriene B4 ( LTB4 ) , Nitric Oxyde ( NO ) implicate inflammation . - NO produced response physical chemical stress bronchial epithelium play critical role small airway remodelling - Exhaled NO concentration usually use monitor bronchial inflammation - The relationship stretch strain small airways bronchial inflammation well understood . - The investigator hypothesis cyclic opening closure peripheral obstruct airways consequent stretch strain act provoke inflammatory response monitor exhaled NO . - The pharmacological effect bronchodilator may play role bronchial inflammation reduce stretch stress bronchiolar wall thus reduce production NO exhalate - Data physiopathological aspect miss literature .</brief_summary>
	<brief_title>Nitric Oxyde Concentration Chronic Obstructive Pulmonary Disease Patients - SANOB Study</brief_title>
	<detailed_description>Bronchial inflammation COPD represent one main cause fully reversible obstruction airflow limitation . The main inflammatory cell involve represent neutrophil , inflammatory mediator like Interleukin-6 ( IL6 ) , Interleukin-8 ( IL8 ) , Interleukin-1 alpha ( IL1alpha ) , Interleukin-1 beta ( IL1beta ) , Tumor Necrosis Factor alfa ( TNFalfa ) , Reactive Oxygen Species ( ROS ) , Leukotriene B4 ( LTB4 ) Nitric Oxide ( NO ) provoke disruption elastic alveolar bond support small airway , thus invalidate physical mechanical characteristic . During tidal volume respiration , patient , chronically obstruct small airway subject , investigator suppose , one follow effect : - total closure small bronchioli cause atelectasis - cyclic opening closure airways thus provoking friction strain stress inflammatory response mechanical origin . The Fraction Exhaled Nitric Oxyde ( FeNO ) concentration largely use clinical practice marker monitor lung inflammatory status . Formoterol Salmeterol two use Long Acting Beta 2 Agonists ( LABA ) inhale therapy COPD , represent basis bronchodilator therapy disease . The purpose study evaluate possible mechanical origin bronchial inflammation capacity inhale LABA acute condition modify trend production NO reduce stretch strain force . Thus possible decline exhale NO concentration use index small airway inflammatory state occur inhaled therapy . To investigator measure exhale NO concentration COPD patient moderate severe obstruction , Forced Expiratory Volume le 70 % predict value ( FEV1 &lt; 70 % pred ) . The evaluation do four different moment : 1. baseline , 72 hour pharmacological washout condition 2. 30 minute assumption inhale therapy ( Salmeterol 50 mcg Formoterol 12 mcg double blind condition ) 3. 60 minute step 2 4. 180 minute step 2 Together NO concentration , also Respiratory Frequency Tidal Volume register evaluation . All subject inpatient access respiratory rehabilitation unit outpatients ambulatory service . After every NO measure , functional respiratory assessment make ( spirometry , plethysmography , Carbon Monoxide ( CO ) diffusion lung test , Single Breath N2 washout test ) , together arterial blood gas analysis . At every step dyspnoea assessment make Visual Analogic Scale , Modified Medical Research Council ( mMRC ) scale assess begin test . Every patient repeat four step assessment 72 hour , double blind pharmacological crossover perform , thus create control study witch every patient , end study , take Salmeterol Formoterol randomize way . For study duration patient perform pharmacological washout ( live short act inhale Beta 2 agonist rescue medication )</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Signature inform consent COPD patient age rag 50 85 year old Patients least history COPD one year COPD patient clinically stable last three month COPD subject FEV1 ( Forced Expiratory Volume 1st second ) &lt; 70 % predict value FEV1/FVC ( Forced Expiratory Volume 1st second/Forced Vital Capacity ) &lt; 88 % ( male ) &lt; 89 % ( female ) LLN ( Low Levels Normality ) COPD former active smoker least smoke history 20 pack year Acute Bronchial Exacerbation recruitment Fertile woman age 18 50 year old active period Pregnancy Subjects enrol clinical trial take part one month precede enrollment . FEV1/FVC 70 % predict value basal condition FEV1 70 % predict value basal condition Known deficit alpha 1 antitrypsin Subjects underwent Lung Volume Reduction Surgery ( LVRS ) Subjects know positivity Human Immunodeficiency Virus ( HIV ) Misuse alcool drug Lack compliance perform respiratory test Subjects capable follow study prescription psychic disorder language problem . Long Term Oxygen Therapy flow &gt; 6 litre per minute ( l/min ) rest</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>COPD</keyword>
	<keyword>bronchial inflammation</keyword>
	<keyword>NO concentration</keyword>
	<keyword>small airway</keyword>
	<keyword>LABA</keyword>
	<keyword>Small Airways Stretching</keyword>
	<keyword>Stretch strain small airway COPD</keyword>
	<keyword>Acute LABA effect NO production</keyword>
	<keyword>Pulmonary desufflation</keyword>
</DOC>